| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3821081 | La Presse Médicale | 2008 | 8 Pages |
Abstract
Despite the inherent complexity in studying pain, it is obvious that several genetic polymorphisms contribute to modulate nociception and the antinociceptive effects of opioids; specifically those involved in pharmacokinetics and the metabolism of opioids (cytochrome P450) and neurotransmitters (catechol-O-methyltransferase), as well as those affecting pharmacodynamics or the drug targets such as the μ-opioid receptor or the unexpected melanocortin 1-receptor.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Ruth Landau,